Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/65673
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaune, B.en
dc.contributor.authorHohoff, C.en
dc.contributor.authorBerger, K.en
dc.contributor.authorNeumann, A.en
dc.contributor.authorMortensen, S.en
dc.contributor.authorRoehrs, T.en
dc.contributor.authorDeckert, J.en
dc.contributor.authorArolt, V.en
dc.contributor.authorDomschke, K.en
dc.date.issued2008en
dc.identifier.citationNeuropsychopharmacology, 2008; 33(4):924-932en
dc.identifier.issn0893-133Xen
dc.identifier.issn1740-634Xen
dc.identifier.urihttp://hdl.handle.net/2440/65673-
dc.description.abstractIn several previous biochemical, pharmacological, and genetic studies, the catechol-O-methyltransferase (COMT) has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of affective disorders. In the present study, 256 patients with major depression (DSM-IV) of Caucasian descent were genotyped for the functional COMT val158met polymorphism and characterized for clinical response to antidepressive pharmacological treatment as measured by intra-individual changes of Hamilton Depression (HAM-D-21) scores over 6 weeks. The COMT 158val/val genotype conferred a significant risk of worse response after 4–6 weeks of antidepressant treatment in patients with major depression (week 4: p=0.003; week 5: p<0.0001; week 6: p<0.0001) after Bonferroni correction for multiple comparisons. The present results strongly point toward a negative influence of the higher activity COMT 158val/val genotype on antidepressant treatment response during the first 6 weeks of pharmacological treatment in major depression, possibly conferred by consecutively decreased dopamine availability. This finding suggests a potentially beneficial effect of an antidepressive add-on therapy with substances increasing dopamine availability individually tailored according to COMT val158met genotype.en
dc.description.statementofresponsibilityBernhard T Baune, Christa Hohoff, Klaus Berger, Anna Neumann, Sünke Mortensen, Tilmann Roehrs, Jürgen Deckert, Volker Arolt and Katharina Domschkeen
dc.language.isoenen
dc.publisherElsevier Science Incen
dc.rights© 2008 Nature Publishing Group. All rights reserved.en
dc.subjectmajor depression; catechol-O-methyltransferase; COMT val158met; polymorphism; antidepressants; treatment responseen
dc.titleAssociation of the COMT val158met Variant with Antidepressant Treatment Response in Major Depressionen
dc.typeJournal articleen
dc.identifier.rmid0020111598en
dc.identifier.doi10.1038/sj.npp.1301462en
dc.identifier.pubid28212-
pubs.library.collectionPsychiatry publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidBaune, B. [0000-0001-6548-426X]en
Appears in Collections:Psychiatry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.